MEI Pharma announced positive preclinical data for its orally administered drug, voruciclib. Voruciclib blocks CDK9, a cyclin-dependent kinase (CDK) inhibitor and hinders growth of KRAS mutant cancers. MEI Pharma’s (MEIP)
MEI Pharma announced positive preclinical data for its orally administered drug, voruciclib. Voruciclib blocks CDK9, a cyclin-dependent kinase (CDK) inhibitor and hinders growth of KRAS mutant cancers. MEI Pharma’s (MEIP)
Xencor presented new data from multiple preclinical studies for XmAb bispecific antibody and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting. Xencor’s
Iovance Biotherapeutics shared clinical data update for Lifileucel used in advanced melanoma from its Cohort 2 in the C-144-01 study. In the study, Lifileucel indicated a 36.4% overall response rate
Sorrento Therapeutics’ subsidiary, Scilex Holding, has received approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for ZTlido to expand its efficacy label.
Sanofi acquired Tidal Therapeutics, a privately held biotechnology company on Friday for an upfront payment of $160 million. The company will pay another $310 million for Tidal contingent upon achieving